Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic ...

BERLIN -- The investigational tyrosine kinase inhibitor (TKI) zanzalintinib plus atezolizumab (Tecentriq) significantly ...

The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by ...

Trageting abnormal brain cells linked to chronic inflammation may be key to treating people with progressive forms of MS, a ...

Australian researchers have uncovered how having children and breastfeeding reduces the long-term risk of an aggressive form ...

Throughout life, our cells are constantly exposed to environmental and internal factors that can damage DNA. While such DNA ...

Tricking cancer cells into self-destructing could reduce risk of recurrence and death in colon cancer by 50%. Results also ...

Breastfeeding seems to cause specialised immune cells to flood into the breasts and stay there for years or even decades, ...

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the ...

The poster for INSIGHT-003 and the Trial in Progress ePoster for TACTI-004 can be found at the Posters & Publications section of Immutep’s website.

Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the ...

CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key ...